ELISA II研究PPT课件.pptVIP

ELISA II Trial ELISA II Trial: Baseline Characteristics ELISA II Trial: Primary Endpoint ELISA II Trial: Secondary Endpoint ELISA II Trial: MI Free Survival at 30 days ELISA II Trial: Bleeding ELISA II Trial Summary Among patients with non-ST elevation MI undergoing angiography with or without revascularization, use of a triple anti-platelet regimen of aspirin, 300mg clopidogrel, and tirofiban was not associated with a difference in the primary endpoint of enzymatic infarct size compared with a dual anti-platelet regimen of aspirin and a 600 mg loading dose of clopidogrel. The secondary endpoi